Domainex

1
UKTI Presentation
2

• Domainex-NCE
• Professor Laurence Pearl
• CSO

3
Achievements to Date

• Founded 2002
• 1.2M Sales
• Customers in Pharmaceuticals and Biotechnology
• 600K in funding to date
• Investment will leverage technology to new
  inflection point
• Competitive advantage
• Patented technology
• Profitable in 2006

4
Management Team

• Keith Powell Chairman
• 21 years in Industry with large and small
  companies
• Eddy Littler CEO
• 17 years in Industry, with Wellcome,
  GlaxoWellcome, Medivir
• Trevor Perrior Research Director,
• More than 20 years in Industry with Zeneca,
  Celltech etc.
• Laurence Pearl, CSO
• ICR Head of Structural Biology

5
Product/Service

• We find new drugs and targets
• Better, faster cheaper!
• Solves the problem of how to reach the difficult
  protein targets
• Study parts not the whole
• Product is a drug/target ready for development

6
Conventional Empirical Strategy
Combinatorial Domain Hunting
7
Technical Strengths

• Biology
• Able to efficiently express technically difficult
  (impossible) proteins or domains-revitalising
  discarded targets for clients or internally
• Chemistry
• Highly experienced scientists able to design and
  synthesise chemical leads for clients and
  internal projects

8
Target Market

• From Small Biotech to large Pharmaceutical
• Size (Contracts from 25,000 to 500,000)
• Growth opportunity for out-license in range
  1m-10M per project
• Opportunity a very large potential market gt10Bn
• Third party research
• London/Cambridge base

9
Research from Business Insights

• Drug targets are generally proteins
• Proteins that interact with small molecules are
  considered the most promising targets
• Overall, enzyme targets account for over 50 of
  marketed drugs
• Outsourcing is playing an increasingly important
  role as a source of leads, as big pharma looks to
  maximize the return from RD budgets.
• Preclinical development, including lead
  optimization, cost the industry 11bn in 2003.

10
Competition
11
Business Model

• Revenue
• Chemistry
• Target domain projects
• Sustainable business
• Long-term customer base
• Expansion strategy
• In-house targets downstream value
• License out pre-expensive development
• Sales and marketing
• Requires small but dedicated team

12
Revenue Model

• Direct Sales (1.5M, 2006)
• Licenses, Royalties (1.5-10M pa)

13
Domainex in short

• Breakthrough technology
• Low burn due to sales
• Potential for high return with reduced risk
• Key targets from internal expertise
• Validated by customers
• Highly experienced management team

14
PROGRESS

• Company A collaboration gave great results and a
  20,000 bonus fee
• Company B collaboration has given three domains
  hopeful for larger follow-on
• Company C close to closing a 6-protein deal
• Internal integration underway
• Internal targets selected